MR
Highly rated in
3
conditions
Highly rated in
3
conditions
Check Dr. Michael E. Rytting's experience treating your condition:
About Dr. Michael E. Rytting

Michael Rytting is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in Holland, Michigan. Rytting has been practicing medicine for over 33 years and is highly rated in 3 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Childhood Pancreatitis, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas and Michigan. Rytting is currently accepting new patients.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 6 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Michael E. Rytting it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Michael E. Rytting accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Priority Health

Call to see if your plan is accepted.
Locations
3235 N Wellness Dr, Holland, MI 49424
Background & Education
Graduate Institution
University Of Michigan Medical School, 1990
Specialties
Pediatrics
Pediatric Hematology Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Holland Hospital
Languages Spoken
English
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors
Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
View 5 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors